louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06719258: Evaluation of Gas Humidification Practices in Patients Under Invasive Mechanical Ventilation
Official title: Evaluation of Gas Humidification Practices in Patients Under Invasive Mechanical Ventilation: Benefit of the F & P950 Heated Humidifier: Comparison With the MR 850 on Clinical Events of Under-humidification
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Humidifier Lung
Mechanical Fragility
Respiratory Complication
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2024-12-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patient in ICU on ventilation will be consider.

Brief summary: When mechanical ventilation is initiated, a humidification method should be chosen. There is two methods: heat and humidity exchanger filters or heated humidity. The second method is recognized to be more efficient, but many external factors can influence its performance. Insufficient humidity results in observable problems, such as difficult management of respiratory secretions.

The study compare two heated humidifiers already used in ICU.

Data will be collected retrospectively from June 1, 2021.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years old
* Admitted to intensive care
* Under invasive mechanical ventilation with the usual indications for the use of a heated humidifier (prolonged invasive mechanical ventilation and / or protective ventilation requiring high respiratory rates.

Exclusion Criteria:

* Mechanical venitilation immediately after surgery (\<24h)
* Imminent extubation or planned intubation of very short duration (\<24h)
* Enrolled in the SAVE-ICU study in the group receiving volatile agents with the AnaConDa system.

Primary outcomes:
measure: Endotracheal tube occlusion requiring emergency tube change
timeFrame: At the end of the mechanical ventilation period or at 21 days ( the first of the 2 occurred)
measure: Bronchoscopy
timeFrame: At the end of the mechanical ventilation period or at 21 days ( the first of the 2 occurred)
measure: Tracheal saline instillations
timeFrame: At the end of the mechanical ventilation period or at 21 days ( the first of the 2 occurred)
measure: Thick secretions
timeFrame: At the end of the mechanical ventilation period or at 21 days ( the first of the 2 occurred)
measure: Change humidifier settings
timeFrame: At the end of the mechanical ventilation period or at 21 days ( the first of the 2 occurred)
Secondary outcomes:
measure: Other elements that may be influenced by the quality of the humidification used during mechanical ventilation
timeFrame: At the end of the mechanical ventilation period or at 21 days ( the first of the 2 occurred)
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: Institut Universitaire de Cardiologie et de Pneumologie de Québec
Study officials:
References:
Clinical trial NCT05120258: Can Subclavian / Infraclavicular Axillary Vein Collapsibility Index Predict Post-Spinal Hypotension in Caesarean Section Operations?
Official title: Subclavian / Infraclavicular Axillary Vein Collapsibility Index in Pregnant Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Post Spinal Hypotension
Keywords: post spinal hypotension, the subclavian vein or infraclavicular axillary vein collapsibility index
Lead sponsor: Selcuk University
Sponsor class: OTHER
First posted: 2021-11-15
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ASA I-II physical status patients scheduled for cesarean section under spinal anesthesia

Brief summary: Postspinal hypotension (PSH) is a common side effect with an incidence of 15.3% to 33%, which may result in organ hypoperfusion and ischemic events (1,2). In pregnant patients, this incidence may increase to 70% and severe PSH may increase the risk of maternal and fetal complications (3). Therefore, it is important for anesthesiologists to estimate the incidence of PSH in cesarean sections and to identify possible mechanisms (4).

One of the important factors affecting the susceptibility of patients to intraoperative hypotension is the preoperative intravascular volume status. Recently, ultrasonography of the central veins has been used frequently by anesthesiologists in the preoperative period in order to evaluate the intravascular volume status (5). Salama and Elkashlan stated that the collapsibility index of the inferior vena cava is a new predictive value for PSH (6). Choi et al. showed that the subclavian vein or infraclavicular axillary vein collapsibility index is an important predictive value for hypotension after induction of general anesthesia (7).

In this study, we wanted to investigate whether the subclavian vein or infraclavicular axillary vein collapsibility index can be used as a predictive value for PSH in cesarean section.


Eligibility criteria: Inclusion Criteria:

* Spinal anesthesia
* ceserean operation
* American Society of Anesthesiologists' (ASA) physical status I-II

Exclusion Criteria:

* Patients who underwent cesarean section in emergency conditions
* Patients who underwent cesarean section under general anesthesia
* American Society of Anesthesiologists' (ASA) physical status III-IV

Primary outcomes:
measure: Predictive value of Subclavian / Infraclavicular Axillary Vein Collapsibility Index for detecting Postspinal hypotension
timeFrame: 45 min
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: selcuk univercity medical faculty
name: Emine ASLANLAR, assis. prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02648958: Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations
Official title: Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Unilateral Total Knee Replacement - a Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arthroplasty, Replacement
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2016-01-07
Enrollment: 68
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Ischemia reperfusion injury causes the release of free oxygen radicals. The selective alpha2-receptor agonist, dexmedetomidine, has an inhibitory effect on inflammatory responses during ischemic injury. The aim of this study is to evaluate the effect of dexmedetomidine on inflammatory responses during ischemia-reperfusion injury in skeletal muscle.


Eligibility criteria: Inclusion Criteria:

* American Society Anesthesiologists classification I-III

Exclusion Criteria:

* use of antioxidants clinically significant cardiovascular, renal, or hepatic diseases heart block greater than the first degree

Primary outcomes:
measure: changes of malondialdehyde (μmol/L)
timeFrame: up to 1 day
Secondary outcomes:
measure: changes of interleukin-6 (pg/ml)
timeFrame: up to 1 day
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance hospital
Study officials:
affiliation: Assistant professor
name: YONGSEON CHOI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05967858: Incidence of Refeeding Syndrome in Consecutively Admitted Patients
Official title: Refeeding Syndrome - Incidence and Risk Factors: An Observational Study on Patients With G-I Disease and Head-neck Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Refeeding Syndrome
Starvation
Phosphate Deficiency
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
First posted: 2023-08-01
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: No other than willingness to participate and consecutively admitted, as well as planned sufficient nutrition

Brief summary: The incidence and main risk-factors analyzed in consecutive in-patients in the departments og gastroenterology and ear-nose and throat diseases (cancer in radiation therapy)

Detailed description: Patients with either parenteral- or tube feeding enter the study to assure sufficient nutrition.

During hospitalization patients were monitored with daily blood samples and clinical evaluation of symptoms in addition to the coverage of energy and protein in percent of estimated needs.

Refeeding phenomenon was defined as a decrease in plasma phosphate after the initiation of nutrition.

Refeeding syndrome as refeeding phenomenon and one or more relevant symptoms in addition (hypotension, cardiac arrhythmia, edema, confusion)

Eligibility criteria: Inclusion Criteria:

* planned tube- or parenteral nutrition (complete or supplementary)
* \> 18 years
* written consent

Exclusion Criteria:

* Renal insufficiency (p-creatinine \>200 micromol/l)
* Lack of ability to communicate (registration of nutritional intake etc)

Primary outcomes:
measure: Refeeding syndrome
timeFrame: 1 week after start of nutrition
Secondary outcomes:
measure: Refeeding phenomenon
timeFrame: 1 week after start of nutrition
Other outcomes:
Locations:
Study officials:
affiliation: University of Copenhagen
name: jens R Andersen, MD, MPA
role: STUDY_CHAIR
References:
Clinical trial NCT06790758: Plasma Rich Fibrin Epidural Injection by Racz Catheter in Postdural Puncture Headache Guided Optic Nerve Sheath Diameter
Official title: Plasma Rich Fibrin Epidural Injection by Racz Catheter in Postdural Puncture Headache Guided Optic Nerve Sheath Diameter
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Plasma Rich Fibrin
Epidural
Racz Catheter
Postdural Puncture Headache
Optic Nerve Sheath Diameter
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-01-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate plasma-rich fibrin epidural injection by Racz catheter in post-dural puncture headaches guided optic nerve sheath diameter.

Detailed description: Postdural puncture headaches (PDPHs) are a recognized complication following unintentional dural puncture during epidural analgesia or intentional dural puncture for spinal anesthesia, diagnostic, or interventional neuraxial procedures.

Plasma-rich fibrin (PRF) is derived from autologous whole blood that contains and releases several different growth factors and cytokines to stimulate the healing of bone and soft tissue via degranulation, which has recently gained popularity in pain management.

Optic nerve sheath diameter (ONSD) is important because the optic nerve is surrounded by subarachnoidal cerebrospinal fluid and all three meningeal layers, and a change in the ONSD can indicate changes in intracranial pressure.

Eligibility criteria: Inclusion Criteria:

* Age from 18 to 65 years.
* Both sexes.
* Patients suffering from severe post-dural puncture headache.

Exclusion Criteria:

* Uncooperative patients.
* Severe comorbid conditions.
* Pregnancy.
* Anticoagulant therapy.
* Known allergies to plasma rich fibrin components.
* Body mass index (BMI) ≥35 kg/m2.

Primary outcomes:
measure: Success rate of the procedure
timeFrame: 24 hours after the intervention
Secondary outcomes:
measure: Degree of pain
timeFrame: 8 days postoperatively
measure: Length of bed rest
timeFrame: 8 days postoperatively
measure: Change in optic nerve sheath diameter
timeFrame: 6 hours after the procedure
measure: Incidence of complications
timeFrame: 8 days postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT06563258: Efficacy of Biodex Balance Training Versus Whole Body Vibration Training in Patients With Knee Osteoarthritis
Official title: Efficacy of Biodex Balance Training Versus Whole Body Vibration Training in Patients With Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-08-20
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A Prospective parallel group single-blind randomized control trial
Primary purpose: TREATMENT

Brief summary: This study will be conducted to answer the research question:

Are there differences between the effect of Biodex balance training and Whole-body vibration training on Knee osteoarthritis?

Detailed description: The purpose of this study is to compare the effects of biodex training balance versus whole body vibration training on Knee osteoarthritis on:

* Pain intensity
* static balance
* dynamic balance
* Functional ability level

Eligibility criteria: Inclusion criteria:

1. Subjects age between (40-60) years old.
2. Radiologic findings had to be compatible with knee OA grade 2 in a simple X ray.
3. Tenderness on medial tibial plateau
4. Intensity of pain: visual analogue scale equal to 5 or greater
5. Failure of two or more types of previous conservative treatment (medication, anti-inflammatory drugs, physical therapy, stretching, acupuncture, orthotics and others) in the last three months

Exclusion Criteria:

1. Neurological and vestibular system disorder, systematic inflammatory disease, steroid injections in the last six months
2. Subjects with diabetes mellitus.
3. acute symptomatic arthritis
4. other conditions (such as osteomyelitis, tuberculosis, and tumor) that affect their walking function; had a contraindication to exercise; and exhibited cognitive impairment

Primary outcomes:
measure: Pain intensity
timeFrame: one month
measure: static balance
timeFrame: one month
measure: Dynamic balance
timeFrame: one month
measure: .Functional abilities
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mti University
Study officials:
References:
Clinical trial NCT03804658: The Factors Affecting the Achievement of Glucose Monitor in the Patients on Diabetes
Official title: The Effects of Glucose Monitor on Patients With Diabetes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Glucose Variability
Cognitive Decline
Keywords: Brain-derived neurotrophic factor
Vascular cell adhesion molecule 1
Renalase
Orexin
Continue glucose monitor
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2019-01-15
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with diabetes both in outpatient and inpatient

Brief summary: To assess the effect of glucose monitors on glucose control and cardiovascular risks.

Detailed description: The investigators will enroll patients with diabetes. The answered questionnaire and blood samples will be collected at baseline. After change the methods or frequency of glucose monitor, the blood samples will be collected again. The investigators will analyze the factors which may affect the glucose control after changes in methods of glucose monitor.

Eligibility criteria: Inclusion Criteria:

* Adults with diabetes

Exclusion Criteria:

* Incooperative patients

Primary outcomes:
measure: Glucose variability
timeFrame: 3 months
Secondary outcomes:
measure: brain-derived neurotrophic factor
timeFrame: 3 months
measure: Orexin
timeFrame: 3 months
measure: Renalase
timeFrame: 3 months
measure: Vascular endothelial cell adhesion molecule 1
timeFrame: 3 months
measure: Health Literacy
timeFrame: 3 months
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Division of Endocrinology and Metabolism in Taichung Veterans General Hospital
Study officials:
affiliation: Taichung Veterans General Hospital
name: I-Te Lee, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06659458: Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
Official title: Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Cancer - Non Small Cell
EGFR Exon 19 Deletion Mutation
Keywords: Lung cancer
EGFR gene
Lead sponsor: Our Lady of the Lake Hospital
Sponsor class: OTHER
First posted: 2024-10-26
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female adult subjects who have EGFR positive lung cancer

Brief summary: EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.


Eligibility criteria: Inclusion Criteria:

* 18-100 years old
* Biologically born female
* Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
* No cancer diagnosis (Arm 2-health control)

Exclusion Criteria:

* less than 18 years of age
* Biologically born male
* Incarcerated at the time of participation

Primary outcomes:
measure: Differences in DNA sequence of EGFR gene
timeFrame: From enrollment to end of data analysis at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Our Lady of the Lake Regional Medical Center
state: Louisiana
Study officials:
References:
Clinical trial NCT06013358: ddcfDNA in Kidney Transplant Recipients
Official title: The Efficacy of Donor-derived Cell-free DNA as a Biomarker for Subclinical Antibody-mediated Rejection in de Novo Anti-HLA DSA-positive Recipients Who Maintain Stable Renal Function After Kidney Transplantation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Kidney Transplant Rejection
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Samsung Medical Center
name: Asan Medical Center
name: Severance Hospital
name: Korea University Anam Hospital
First posted: 2023-08-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Recipients with de novo DSA positivity post-kidney transplantation maintaining stable renal function

Brief summary: The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation. This will be achieved through the measurement of donor-derived cell-free DNA. The utility of donor-derived cell-free DNA will be validated based on histological findings using Receiver Operating Characteristics (ROC) curve analysis.


Eligibility criteria: Inclusion Criteria:

* Recipients aged 18 and above
* Patients with de novo DSA positivity post-kidney transplantation and stable renal function: De novo HLA DSAs encompass both class I and class II, with Mean Fluorescence Intensity (MFI) greater than 1000. Stable renal function is defined as serum creatinine variation of less than 15% compared to the last 6 months.
* Patients with detected de novo HLA-DSAs but did not undergo histological examinations.

Exclusion Criteria:

* Multi-organ transplant recipients
* Recipients with positive preformed DSAs
* ABO-incompatible transplant recipients
* Pediatric recipients under 18 years old at the time of transplantation
* Recipients lost to follow-up observation
* atients already subjected to histological examinations due to positive De novo HLA-DSAs.

Primary outcomes:
measure: diagnostic accuracy of subclinical ABMR
timeFrame: 10 years within kidney transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT05321758: Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
Official title: Repeated and Multiple Fecal Microbiota Transplantations Plus Partial Enteral Nutrition as the First-line Treatment in Active Pediatric Crohn's Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Crohn Disease
Keywords: Crohn Disease;fecal microbiota transplantation
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2022-04-11
Enrollment: 50
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Partial enteral nutrition,FMT
Primary purpose: TREATMENT

Brief summary: To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.

Detailed description: Recent studies have suggested that gut imbalance and deregulation of immunological responses plays a pivotal role in the disease development of Crohn's disease (CD), and that FMT could be a useful treatment. Our study is aims to repeated and multiple FMTs plus PEN as a first-line treatment for active Crohn's disease (CD) in children. The patients were divided into 2 groups voluntarily. Patients treated with FMT coupled with PEN were defined as the FMT group, and those treated with PEN combined with Immunosuppressants (hormones, azathioprine, thalidomide) served as the Immunosuppressive group. The therapeutic effect of the two groups was compared. In the induction stage of CD, FMT group received FMT and PEN intervention, and FMT was given 1-3 courses, 3-6 times per course. The transplantation routes include oral capsule, enema and/or colonoscopy. All the patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.

Eligibility criteria: Inclusion Criteria:

age of older than 2 years and younger than 16 years with no genetic diseases; newly diagnosed with mild-to-moderate CD ( defined by the PCDAI of \>10 and ≤40, and SES-CD of \>3); Subjects with no change in medication or dose at least 1 week prior to transplantation; agree to received regularly colonoscopy

Exclusion Criteria:

patients who were treated with corticosteroids, methotrexate, thiopurines, and anti-TNF agents as their first-line treatment

Primary outcomes:
measure: Clinical remission
timeFrame: 8-12 weeks after FMT
measure: Endoscopic remission
timeFrame: 8-12 weeks after FMT
measure: Mucosal healing
timeFrame: 8-12 weeks after FMT
Secondary outcomes:
measure: Adverse events
timeFrame: 2 and 10 weeks after FMT
Other outcomes:
measure: gut microbial
timeFrame: before treatment and 5-10 weeks after treatment
Locations:
city: Wuhan
country: China
facility: Tongji Hospital
state: Hubei
Study officials:
affiliation: Tongji Hospital
name: Zhihua Huang
role: STUDY_DIRECTOR
References: